Кобалава ж д артериальная гипертония
1. An MM, Zou Z, Shen H, Liu P, Chen ML, Cao YB et al. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol. 2010;66(8):813–21.
2. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009;48(1):9. doi:10.1080/02841860802314720
3. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9(2):117–23.
4. Qi WX, Lin F, Sun YJ, Tang LN, He AN, Yao Y et al. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. Cancer Chemother Pharmacol. 2013;71(2): 431–9.
5. Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. 2015;121(2):311–9.
6. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–30.
7. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358 (19):2039–2049.
8. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system. Circulation. 2011;124(15):1687–1691. doi:10.1161/CIRCULATIONAHA.110.992230
9. Hayman SR, Leung N, Grande JP, Garovic VD.VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep. 2012;14(4):285–94.
10. Zerbini G, Lorenzi M, Palini A. Tumor angiogenesis. N Engl J Med. 2008;359(7):763; author reply 764.
11. Carter JJ, Fretwell LV, Woolard J. Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats. FASEB J. 2017;31(3):1193–1203. doi:10.1096/fj.201600749R
12. Thijs AM, van Herpen CM, Sweep FC, Geurts-Moespot A, Smits P, van der Graaf WT et al. Role of endogenous vascular endothelial growth factor in endothelium-dependent vasodilation in humans. Hypertension. 2013;61(5):1060–1065. doi:10.1161/HYPERTENSIONAHA.111.00841
13. Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56(4):675–81. doi:10.1161/HYPERTENSIONAHA.109.149690
14. Verdonk K, Saleh L, Lankhorst S, Smilde JE, van Ingen MM, Garrelds IM et al. Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression. Hypertension. 2015;65(6):1316–1323. doi:10.1161/HYPERTENSIONAHA.115.05267
15. Lankhorst S, Kappers MH, van Esch JH, Smedts FM, Sleijfer S, Mathijssen RH et al. Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study. Hypertension. 2014;64(6):1282–1289. doi:10.1161/HYPERTENSIONAHA.114.04187
16. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signaling and therapeutic inhibition. Cell Signal. 2007:19(10);2003–12.
17. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008;19(5):927–34.
18. Steeghs N, Gelderblom H, Roodt JO, Christensen O, Rajagopalan P, Hovens M et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res. 2008;14(11):3470–6. doi:10.1158/1078-0432.CCR-07-5050
19. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR et al. Mechanisms of hypertension associated with BAY 43–9006. J Clin Oncol. 2006;24(9):1363–9.
20. Touyz RM, Lang NN, Herrmann J, van den Meiracker AH, Danser AHJ. Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition. Hypertension. 2017;70(2):220–226. doi:10.1161/HYPERTENSIONAHA.117.08856
21. Schneider BP, Li L, Shen F, Miller KD, Radovich M, O’Neill A et al. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer. 2014;111(6):1241. doi:10.1038/bjc.2014.430
22. Sibertin-Blanc C, Mancini J, Fabre A, Lagarde A, Del Grande J, Levy N et al. Vascular endothelial growth factor a c.*237C > T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer. Dig Liver Dis. 2015;47(4):331. doi:10.1016/j.dld.2014.12.013
23. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology. Eur Heart J. 2016;37(36):2768–2801. doi:10.1093/eurheartj/ehw211
24. Maitland LM, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ et al. Initial assessment, surveillance and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102 (9):596–604. doi:10.1093/jnci/djq091
25. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–630.
26. Mir O, Ropert S, Alexandre J, Goldwasser F. Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol. 2009;20(5):967–970.
27. Rini BI, Cohen DP, Lu D, Chen I, Hariharan S, Gore ME et al. Hypertension (HTN) as a biomarker of efficacy in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib. J Natl Cancer Inst. 2011 May 4;103(9):763–73. doi:10.1093/jnci/djr128
28. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic metaanalysis. Cancer Chemother Pharmacol. 2010;66(2):357. doi:10.1007/s00280-009-1170-y
29. Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA et al. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist. 2013;18(3):273. doi:10.1634/theoncologist.2012-0339
30. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441–2447.
31. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370 (9604):2011–2019.
32. Maitland ML, Kasza KE, Karrison TG, Moshier K, Sit L, Black HR et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009;15(19):6250–6257. doi:10.1158/1078-0432.CCR-09-0058
33. Диагностика и лечение артериальной гипертензии. Российские рекомендации, четвертый пересмотр. Систем-ные гипертензии. 2010;3:5–26. [Diagnostics and management of arterial hypertension. Russian guidelines, 4th edition. Systemic Hypertension. 2010;3:5–26. In Russian].
34. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M et al. 2013 The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34 (28):2159–2219.
35. Mir O, Coriat R, Cabanes L, Ropert S, Billemont B, Alexandre J et al. An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist. 2011;16(9):1325–1332. doi:10.1634/theoncologist.2010–0002
36. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med. 2008;358 (1):95–97.
37. Robinson ES, Matulonis UA, Ivy P, Berlin ST, Tyburski K, Penson RT et al. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol. 2010;5(3):477–483. doi:10.2215/CJN.08111109
38. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49(2):186–93.
39. Lankhorst S, Baelde HJ, Clahsen-van Groningen MC, Smedts FM, Danser AH, van den Meiracker AH. Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib. Nephrol Dial Transplant. 2016;31(6):914–921. doi:10.1093/ndt/gfv410
40. Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010;1(7):628–38.
41. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K et al. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol. 2011;29(19):2635–44.
42. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011;29(19):2645–52. doi:10.1200/JCO.2010.33.4441
43. Zhang D, Ma QY, Hu HT, Zhang M. Beta2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting creb, nfkappab and ap-1. Cancer Biol Ther. 2010;10(1):19–29.
44. Liao X, Che X, Zhao W, Zhang D, Bi T, Wang G. The betaadrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor kappa-b signaling. Oncol Rep. 2010;24(6):1669–76.
45. Park PG, Merryman J, Orloff M, Schuller HM. Betaadrenergic mitogenic signal transduction in peripheral lung adenocarcinoma: implications for individuals with preexisting chronic lung disease. Cancer Res. 1995;55(16):3504–8.
46. Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res. 2006;66(21):10357–64.
47. Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res. 2006;12(2):369–75.
48. Pasquier E, Ciccolini J, Carre M, Giacometti S, Fanciullino R,Pouchy C et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2011;2(10):797–809.
Источник
1. Шальнова С. А., Деев А. Д., Оганов Р. Г., Шестов Д. Б. Роль систолического и диастолического артериального давления для прогноза смертности от сердечно-сосудистых заболеваний. Кардиоваскулярная терапия и профилактика. 2002;1:10–15. [Shalnova SA, Deev AD, Oganov RG, Shestov DB. The prognostic role of systolic and diastolic blood pressure for cardiovascular morbidity. Kardiovaskulyarnaya Terapiya i Profilaktika = Cardiovascular Therapy and Prevention. 2002;1:10–15 In Russian].
2. Моисеев В. С., Кобалава Ж. Д. АРГУС: артериальная гипертония у лиц старших возрастных групп. М.: МИА, 2002. 448 с. [Moiseev VS, Kobalava ZhD. ARGUS: hypertension in elderly patients. M.: MIA, 2002. 448 p. In Russian].
3. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757–764.
4. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. J Am Med Assoc. 1991;265 (24):3255–3264.
5. Lindholm LH, Hansson L, Dahlöf B, Ekbom T, Hedner T, De Faire U et al. The Swedish Trial in old patients with hypertension-2 (STOP-hypertension-2): a progress report. Blood Press. 1996;5 (5):300–304.
6. Agnoletti D, Zhang Yi, Borghi C, Blacher J, Safar ME. Effects of antihypertensive drugs on central blood pressure in humans: a preliminary observation. Am J Hypertens. 2013;26 (8):1045–1052.
7. Rimoldi SF, Messerli FH, Chavez P, Stefanini GG, Scherrer U et al. Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive patients: a meta-analysis. J Clin Hypertens. 2015;17(3):193–199.
8. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011;123(21):2434–2506.
9. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the management of arterial hypertenion. J Hypertens. 2018;36 (12):2284–2309. doi:10.1097/HJH.0000000000001961
10. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in highrisk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–2997.
11. Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens. 1998;16(12 Pt 1): 1823.
12. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23): 2417–2428.
13. Baguet JP, Legallicier B, Auquier P, Robitail S. Updated meta-analytical approach to efficacy of antihypertensive drugs in reducing blood pressure. Clinical Drug Invest. 2007;27(11):735– 753.
14. Кобалава Ж. Д., Шаварова Е. К. Клинические особенности артериальной гипертонии в пожилом и старческом возрасте и обоснование применения комбинации амлодипин/индапамид ретард. Кардиология. 2017;57(8):60–70. [Kobalava ZhD, Shavarova EK. Clinical features of arterial hypertension in the elderly and senile age and the rationale for using the combination of amlodipine/indapamide-retard. Kardiologiia. 2017;57(8):60–70. In Russian].
15. Alderman MH, Cohen HW, Sealey JE, Laragh JH. Pressor responses to antihypertensive drug types. Am J Hypertens. 2010;23 (9):1033–1037.
16. Furberg CD. Renin-guided treatment of hypertension: time for action. Am J Hypertens. 2010;23(9):929–930.
17. Brown MJ. Heterogeneity of blood pressure response to therapy. Am J Hypertens. 2010;23(9):926–928.
18. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D et al. on behalf the CAFÉ Investigators. Differential impact of blood pressure — lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213–1225.
19. Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. Hypertension. 2009;54(6): 1328–1336.
20. Burke GL, Bertoni AG, Shea S, Tracy R, Watson KE, Blumenthal RS, et al. The impact of obesity on cardiovascular disease risk factors and subclinical vascular disease: the MultiEthnic Study of Atherosclerosis. Arch Intern Med. 2008;168 (9):928–935.
21. Mitchell GF, Hwang S-J, Vasan RS, Larson MG, Pencina MJ, Hamburg NM et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation. 2010;121(4):505–511.
Источник
1. Guidelines Sub-Committee. 2003 European Society of Hypertension — European Society of Cardiology guidelines for the management of arterial hypertension // J. Hypertens. — 2003. — Vol. 21, № 6. — P. 1011–1053.
2. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G. et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension // J. Hypertens. — 2007. — Vol. 25, № 9. — P. 1105–1187.
3. Mancia G., Fagard R., Narkiewicz R., Redon J., Zanchetti A., Bohm M. et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension // J. Hypertens. — 2013. — Vol. 31, № 7. — P. 1281–1357.
4. ESH/ESC Task Force for the management of arterial hypertension. 2013 Practice Guidelines for the management of (ESH) and the European Society of Cardiology (ESC) // J. Hyper- inhibitor or calcium channel blocker vs diuretic: The Antihypertens. — 2013. — Vol. 31, № 10. — P. 1925–1938.
5. Mancia G., Laurent S., Agabiti-Rosei E., Ambrosioni E., Burnier M., Caulield M.J. et al. Reappraisal of the European guidelines on hypertension management: a European Society of Hypertension Task Force document // J. Hypertens. — 2009. — Vol. 27, № 11. — P. 2121–2158.
6. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. — 2008. — Vol. 358, № 24. — P. 2560–2572.
7. Beckett N.S., Peters R., Fletcher A.E., Staessen J.A., Liu L., Dumitrascu D. et al. Treatment of hypertension in patients 80 years of age or older // N. Engl. J. Med. — 2008. — Vol. 358, № 18. — P. 1887–1898.
8. Yusuf S., Diener H.C., Sacco R.L., Cotton D., Ounpuu S., Lawton W.A. et al. Telmisartan to prevent recurrent stroke and cardiovascular events // N. Engl. J. Med. — 2008. — Vol. 359, № 12. — Р. 1225–1237.
9. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events // N. Engl. J. Med. —2008. — Vol. 358, № 15. — P. 1547–1559.
10. Telmisartan Randomized Assessment Study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial // Lancet. — 2008. — Vol. 372, № 9644. — P. 1174–1183.
11. Jamerson K., Weber M.A., Bakris G.L., Dahlof B., Pitt B., Shi V. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients // N. Engl. J. Med. — 2008. — Vol. 359, № 23. — P. 2417–2428.
12. The ACCORD Study Group. Effects of intensive blood pressure control in type 2 diabetes mellitus // N. Engl. J. Med. — 2010. — Vol. 362, № 17. — P. 1575–1585.
13. Sandset E.C., Bath P.M., Boysen G., Jatuzis D., Korv J., Luders S. et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial // Lancet. — 2011. — Vol. 377, № 9767. — P. 741–750
14. Haller H., Ito S., Izzo J.L., Januszewicz A., Katayama S., Menne J. et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes // N. Engl. J. Med. — 2011. — Vol. 364, № 10. — P. 907–917.
15. Parving H.H., Brenner B.M., McMurray J.V., de Zeeuw D., Haffer S.M., Solomon S.D. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes // N. Engl. J. Med. — 2012. — Vol. 367, № 23. — P. 2204–2213.
16. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations
17. from prospective epidemiological studies // Br. Med. J. — 2009. —Vol. 338. — 1665 p.
18. Williams B., Lacy P.S., Thom S.M., Cruickshank K., Stanton A., Collier D. et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study // Circulation. — 2006. — Vol. 113, № 9. — P. 1213–1225.
19. Boutouyrie P., Achouba A., Trunet P., Laurent S. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study // Hypertension. — 2010. — Vol. 55, № 6. — P. 1314–1322.
20. ALLHAT oficers and co-ordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // J. Am. Med. Assoc. — 2002. — Vol. 288, № 23. — P. 2981–2997.
21. Silvestri A., Galetta P., Cerquetani E., Marazzi G., Patrizi R., Fini M., Rosano G.M. Report of erectile dysfunction after therapy with beta blockers is related to patient knowledge of side- efects and is reversed by placebo // Eur. Heart. J. — 2003. — Vol. 24, № 21. — P. 1928–1932.
22. Hansson L., Lindholm L.H., Ekbom T., Dahlof B., Lanke J., Schersten B. et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study // Lancet. — 1999. — Vol. 354, № 9192. — P. 1751–1756.
23. Rutten F.H., Zuithoff N.P., Halk F., Grobbee D.E., Hoes A.W. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease // Arch. Intern. Med. — 2010. — Vol. 170, № 10. — P. 880–887.
24. National Institute for Health and Clinical Excellence. Hypertension (CG127): clinical management of primary hypertension in adults. https://www.nice.org.uk/guidance/CG127.
25. Zanchetti A., Mancia G. Longing for clinical excellence: a critical outlook into the NICE recommendations on hypertension managemen this nice always good? // J. Hypertens. — 2012. — Vol. 30, № 4. — P. 660–668.
26. Zanchetti A. Hypertension meta-analyses: irst rank evidence or second hand information? // Nat. Rev. Cardiol. — 2011. — Vol. 8, № 5. — P. 249–251.
27. Messerli F.H., Makani H., Benjo A., Romero J., Alviar C., Bangalore S. Antihypertensive eficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring. A meta-analyses of randomized trials // J. Am. Coll. Cardiol. — 2011. — Vol. 57, № 5. — P. 590–600.
28. Roush G.C., Holford T.R., Guddati A.K. Chlortalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses // Hyperten-sion. — 2012 — Vol. 59, № 6. — P. 1110–1117.
29. Dorsch M.P., Gillespie B.W., Erickson S.R., Bleske B.E., Weder A.B. Chlortalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis // Hypertension. — 2011. — Vol. 57, № 4. — P. 689–694.
30. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials // Arch. Intern. Med. — 2005. — Vol. 165, № 12. — P. 1410–1419.
31. Verdecchia P., Reboldi G., Angeli F., Gattobigio R., Bentivoglio M., Thijs L. et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention // Hypertension. — 2005. — Vol. 46, № 2. — P. 386–392.
32. Strauss M.H., Hall A.S. Do angiotensin receptor blockers increase the risk of myocardial infarction? Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox // Circulation. — 2006. — Vol. 114, № 8. —P. 838–854.
33. van Vark L.C., Bertrand M., Akkerhuis K.M., Brugts J.J., Fox K., Mourad J.J., Boersma E. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients // Eur. Heart. J. — 2012. — Vol. 33, № 16. — P. 2088–2097.
34. Liu L., Zhang Y., Liu G., Li W., Zhang X., Zanchetti A. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo controlled trial in Chinese hypertensive patients // J. Hypertens. — 2005. — Vol. 23, № 12. — P. 2157–2172.
35. Dalhof B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., aulield M. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required vs. atenolol adding bendrolumethiazide as required in the Anglo-Scandinavian. Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA) a multicentre randomised controlled trial // Lancet. — 2005. — Vol. 366, № 9489. — P. 895–906.
36. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U. et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol // Lancet. — 2002. — Vol. 359, № 9311. — P. 995–1003.
37. Hansson L., Lindholm L.H., Niskanen L., Lanke J., Hedner T., Niklason A. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial // Lancet. — 1999. — Vol. 353, № 9153. — P. 611–616.
38. Hansson L., Hedner T., Lund-Johansen P., Kjeldsen S.E., Lindholm L.H., Sylversten J.O. et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study // Lancet. — 2000. — Vol. 356, № 9227. — P. 359–365.
Источник
